150 related articles for article (PubMed ID: 17393574)
1. Viewpoint: Terje R. Pedersen, MD, PhD. Interview by Robert Short.
Pedersen TR
Circulation; 2007 Mar; 115(12):f51-2. PubMed ID: 17393574
[No Abstract] [Full Text] [Related]
2. Controversies in dyslipidemias: atheroprevention in diabetes and insulin resistance.
Brinton EA
Ann N Y Acad Sci; 2005 Dec; 1055():159-78. PubMed ID: 16387723
[TBL] [Abstract][Full Text] [Related]
3. The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
Manuel DG; Tanuseputro P; Mustard CA; Schultz SE; Anderson GM; Ardal S; Alter DA; Laupacis A
CMAJ; 2005 Apr; 172(8):1027-31. PubMed ID: 15824409
[No Abstract] [Full Text] [Related]
4. Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.
Davidson MH
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1582-3. PubMed ID: 18716322
[No Abstract] [Full Text] [Related]
5. Should all patients with systemic lupus erythematosus receive cardioprotection with statins?
Toloza S; Urowitz MB; Gladman DD
Nat Clin Pract Rheumatol; 2007 Oct; 3(10):536-7. PubMed ID: 17700557
[No Abstract] [Full Text] [Related]
6. Intensive cholesterol lowering: no longer a myth.
Bitzur R; Harats D
Isr Med Assoc J; 2005 Dec; 7(12):816-7. PubMed ID: 16382708
[No Abstract] [Full Text] [Related]
7. Coronary heart disease and dyslipidemia: a cross-sectional evaluation of prevalence, current treatment, and clinical control in a large cohort of Spanish high-risk patients: the PRINCEPS study.
de Rojas FD; De Frutos T; Ponte A; Chacón JM; Vitale GC;
Prev Cardiol; 2009; 12(2):65-71. PubMed ID: 19476579
[TBL] [Abstract][Full Text] [Related]
8. Achieving cholesterol goals. Current and future drug therapies.
Jones PH
Postgrad Med; 2003 Aug; 114(2 Suppl):14-21. PubMed ID: 19667635
[TBL] [Abstract][Full Text] [Related]
9. New options in lipid management--can we extend the benefits of current therapy? Introduction.
Gotto AM; Paoletti R
Am Heart J; 2002 Dec; 144(6 Suppl):S19-20. PubMed ID: 12486411
[No Abstract] [Full Text] [Related]
10. Causal mechanism for atherosclerosis or coronary heart disease in women: a constellation of components.
Agrinier N; Cournot M; Ruidavets JB; Ahluwalia N; Ferrières J
Maturitas; 2010 Apr; 65(4):404-5. PubMed ID: 20181447
[No Abstract] [Full Text] [Related]
11. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
[No Abstract] [Full Text] [Related]
12. [Diabetic dyslipoproteinemia: beyond LDL].
Merkel M
Dtsch Med Wochenschr; 2009 May; 134(20):1067-73. PubMed ID: 19421932
[TBL] [Abstract][Full Text] [Related]
13. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
Van Ganse E; Laforest L; Burke T; Phatak H; Souchet T
Clin Ther; 2007 Aug; 29(8):1671-81. PubMed ID: 17919548
[TBL] [Abstract][Full Text] [Related]
14. [Combination pharmacotherapy therapy in the management of atherogenic dyslipidemia].
Kłosiewicz-Latoszek L; Cybulska B
Kardiol Pol; 2005 Jun; 62 Suppl 2():II76-80. PubMed ID: 19813341
[No Abstract] [Full Text] [Related]
15. Reshaping the dyslipidemia management paradigm.
Guthrie RM
Postgrad Med; 2003 Aug; 114(2 Suppl):7-13. PubMed ID: 19667634
[TBL] [Abstract][Full Text] [Related]
16. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
[TBL] [Abstract][Full Text] [Related]
17. Lipid management in the geriatric patient.
Nair AP; Darrow B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
[TBL] [Abstract][Full Text] [Related]
18. The use of lipid-lowering drug therapy in children and adolescents.
Avis HJ; Vissers MN; Wijburg FA; Kastelein JJ; Hutten BA
Curr Opin Investig Drugs; 2009 Mar; 10(3):224-31. PubMed ID: 19333879
[TBL] [Abstract][Full Text] [Related]
19. Statins, cholesterol, and the prevention of coronary heart disease.
Freeman MW
FASEB J; 2006 Feb; 20(2):200-1. PubMed ID: 16449790
[No Abstract] [Full Text] [Related]
20. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
